149 related articles for article (PubMed ID: 24093543)
1. Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.
Pea F
Expert Rev Anti Infect Ther; 2013 Oct; 11(10):989-97. PubMed ID: 24093543
[TBL] [Abstract][Full Text] [Related]
2. Combination antifungal therapy for invasive fungal infections in children and adults.
Hatipoglu N; Hatipoglu H
Expert Rev Anti Infect Ther; 2013 May; 11(5):523-35. PubMed ID: 23627858
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin in the treatment of patients with invasive candidiasis.
Kett DH; Cubillos GF
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic implications for use of antifungal agents.
Lewis RE
Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480
[TBL] [Abstract][Full Text] [Related]
5. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
Jullien V
Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
[TBL] [Abstract][Full Text] [Related]
7. [Fungal infection secondary to treatment of Escherichia coli in a critically ill patient].
Maack KH; Tarp B
Ugeskr Laeger; 2012 Aug; 174(35):1997-8. PubMed ID: 22929579
[TBL] [Abstract][Full Text] [Related]
8. Invasive candidiasis in the ICU: evidence based and on the edge of evidence.
Hollenbach E
Mycoses; 2008 Sep; 51 Suppl 2():25-45. PubMed ID: 18721330
[TBL] [Abstract][Full Text] [Related]
9. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
10. Anidulafungin: when and how? The clinician's view.
George J; Reboli AC
Mycoses; 2012 Jan; 55(1):36-44. PubMed ID: 21668526
[TBL] [Abstract][Full Text] [Related]
11. Antifungal PK/PD considerations in fungal pulmonary infections.
Lepak AJ; Andes DR
Semin Respir Crit Care Med; 2011 Dec; 32(6):783-94. PubMed ID: 22167406
[TBL] [Abstract][Full Text] [Related]
12. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.
Keane S; Geoghegan P; Povoa P; Nseir S; Rodriguez A; Martin-Loeches I
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):839-847. PubMed ID: 30257597
[TBL] [Abstract][Full Text] [Related]
13. Candida endophthalmitis: focus on current and future antifungal treatment options.
Khan FA; Slain D; Khakoo RA
Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
[TBL] [Abstract][Full Text] [Related]
14. Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
Ericson J; Manzoni P; Benjamin DK
Early Hum Dev; 2013 Jun; 89 Suppl 1(0 1):S25-7. PubMed ID: 23809344
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B.
Sandovsky-Losica H; Shwartzman R; Lahat Y; Segal E
J Antimicrob Chemother; 2008 Sep; 62(3):635-7. PubMed ID: 18490373
[No Abstract] [Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
17. Update on echinocandin antifungals.
Kauffman CA; Carver PL
Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
[TBL] [Abstract][Full Text] [Related]
18. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
19. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
